Use of eltrombopag in thrombocytopenia of liver disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Pharmacol. Dec 9, 2014; 3(4): 186-192
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.186

Table 1 Mechanisms of thrombocytopenia in liver disease

In chronic liver disease

Decreased Thrombopoietin production

Splenic sequestration

Autoantibodies against platelets

Expansion of plasma volume

Bone marrow suppression (Alcohol)

In specific liver diseases

Viral or alcohol related marrow suppression

Autoimmune thrombocytopenia

Cryoglobulins

Drugs: Interferon mediated marrow suppression

Citation: Sharma V. Use of eltrombopag in thrombocytopenia of liver disease. World J Pharmacol 2014; 3(4): 186-192
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/186.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.186

Sharma V. Use of eltrombopag in thrombocytopenia of liver disease. World J Pharmacol 2014; 3(4): 186-192 [DOI: 10.5497/wjp.v3.i4.186]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.